I would certainly embrace Mr. Ethier's recommendation that there be a greater shared responsibility and a greater responsibility on the part of industry.
To bring in the element of the previous question on how to deal with the in-commerce list, some of these substances are pharmaceuticals or the substances contained within pharmaceuticals. Since CEPA came into force, we've had a great deal of evidence on the very environmental effects of pharmaceuticals in water and the resulting impact both on the environment and, indeed, on human health.
I again think that this committee needs to look at the adequacy of the new substances notification framework for regulating those or first looking at them and then potentially regulating them. This is the ideal opportunity to do that, because of those effects.
Thank you, Mr. Chair.